Novavax, Inc, an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases said its vaccine is 100 percent effective at protecting against moderate to severe COVID-19 and 90.4 percent effective overall.
Available data came from a phase 3 trial that enrolled 29,960 participants across 119 sites in the U.S. and Mexico indicates. Novavax said it recruited participants from the communities and demographic groups most affected by COVID-19. Should the vaccine be cleared by the FDA, Novavax is ready to manufacture 150 million doses each month by the end of 2021.
The company’s scientist prior to 2020, developed experimental vaccines for Ebola, influenza, respiratory syncytial virus, and other emerging infectious diseases.
According to WHO, equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines the world body stated on its website.
According to the global body, safe and effective vaccines are a game-changing tool: but for the foreseeable future we must continue wearing masks, cleaning our hands, ensuring good ventilation indoors, physically distancing and avoiding crowds.
Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmission.
But it’s not vaccines that will stop the pandemic, it’s vaccination. We must ensure fair and equitable access to vaccines, and ensure every country receives them and can roll them out to protect their people, starting with the most vulnerable. ALSO READ: Pros and Cons Of COVID-19 Vaccines